Market Closed -
Nasdaq
21:00:00 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
28.76
USD
|
+2.46%
|
|
+2.31%
|
+2.39%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
19,426
|
17,116
|
17,432
|
12,497
|
12,970
|
-
|
-
|
Enterprise Value (EV)
1 |
23,181
|
22,089
|
22,814
|
18,155
|
18,716
|
18,909
|
18,705
|
P/E ratio
|
31.2
x
|
39
x
|
558
x
|
11.1
x
|
12.3
x
|
11.8
x
|
9.68
x
|
Yield
|
0.6%
|
1.71%
|
1.92%
|
2.85%
|
3.06%
|
3.33%
|
3.26%
|
Capitalization / Revenue
|
9.15
x
|
7.48
x
|
7.79
x
|
5.31
x
|
4.88
x
|
4.41
x
|
4.08
x
|
EV / Revenue
|
10.9
x
|
9.65
x
|
10.2
x
|
7.71
x
|
7.04
x
|
6.43
x
|
5.89
x
|
EV / EBITDA
|
14.3
x
|
11.4
x
|
8.89
x
|
6.47
x
|
7.53
x
|
6.9
x
|
6.24
x
|
EV / FCF
|
11.4
x
|
12.5
x
|
10.2
x
|
6.7
x
|
19.8
x
|
15.1
x
|
12.7
x
|
FCF Yield
|
8.78%
|
8%
|
9.8%
|
14.9%
|
5.06%
|
6.63%
|
7.89%
|
Price to Book
|
3.07
x
|
2.36
x
|
2.52
x
|
1.66
x
|
1.29
x
|
1.19
x
|
1.09
x
|
Nbr of stocks (in thousands)
|
388,132
|
429,511
|
441,104
|
444,886
|
450,981
|
-
|
-
|
Reference price
2 |
50.05
|
39.85
|
39.52
|
28.09
|
28.76
|
28.76
|
28.76
|
Announcement Date
|
17/02/21
|
15/02/22
|
15/02/23
|
15/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,122
|
2,289
|
2,237
|
2,355
|
2,657
|
2,941
|
3,175
|
EBITDA
1 |
1,621
|
1,944
|
2,566
|
2,806
|
2,484
|
2,739
|
2,997
|
EBIT
1 |
1,598
|
1,921
|
2,560
|
2,806
|
2,156
|
2,370
|
2,727
|
Operating Margin
|
75.31%
|
83.92%
|
114.44%
|
119.14%
|
81.15%
|
80.58%
|
85.89%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
230
|
1,700
|
1,304
|
1,438
|
-
|
Net income
1 |
975
|
620
|
43
|
1,135
|
1,048
|
1,080
|
1,295
|
Net margin
|
45.95%
|
27.09%
|
1.92%
|
48.2%
|
39.45%
|
36.71%
|
40.78%
|
EPS
2 |
1.606
|
1.021
|
0.0708
|
2.530
|
2.340
|
2.435
|
2.970
|
Free Cash Flow
1 |
2,035
|
1,767
|
2,235
|
2,708
|
947
|
1,253
|
1,475
|
FCF margin
|
95.88%
|
77.18%
|
99.92%
|
115%
|
35.64%
|
42.61%
|
46.45%
|
FCF Conversion (EBITDA)
|
125.52%
|
90.88%
|
87.11%
|
96.51%
|
38.12%
|
45.74%
|
49.22%
|
FCF Conversion (Net income)
|
208.68%
|
284.94%
|
5,198.2%
|
238.6%
|
90.35%
|
116.07%
|
113.9%
|
Dividend per Share
2 |
0.3000
|
0.6800
|
0.7600
|
0.8000
|
0.8796
|
0.9566
|
0.9379
|
Announcement Date
|
17/02/21
|
15/02/22
|
15/02/23
|
15/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
586
|
576
|
562
|
536
|
573
|
566
|
684
|
538
|
536.3
|
596
|
709.4
|
628.8
|
694.2
|
662.9
|
-
|
EBITDA
1 |
533
|
494
|
556
|
480
|
548
|
983
|
1,044
|
498
|
582.2
|
682
|
637.6
|
589.6
|
648.2
|
605.4
|
701
|
EBIT
1 |
527
|
488
|
550
|
480
|
548
|
983
|
1,044
|
498
|
582.2
|
681.7
|
541.2
|
463.8
|
481.5
|
561.5
|
-
|
Operating Margin
|
89.93%
|
84.72%
|
97.86%
|
89.55%
|
95.64%
|
173.67%
|
152.63%
|
92.57%
|
108.56%
|
114.38%
|
76.29%
|
73.76%
|
69.36%
|
84.7%
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
102
|
8
|
52
|
305
|
143
|
-456
|
-
|
-
|
-
|
494
|
239.6
|
-6.24
|
46.86
|
484.2
|
-
|
Net margin
|
17.41%
|
1.39%
|
9.25%
|
56.9%
|
24.96%
|
-80.57%
|
-
|
-
|
-
|
82.89%
|
33.78%
|
-0.99%
|
6.75%
|
73.04%
|
-
|
EPS
2 |
0.1680
|
0.0132
|
0.0857
|
0.5025
|
0.2360
|
-0.7512
|
-
|
-
|
-
|
1.100
|
0.5400
|
-0.0100
|
0.1000
|
1.080
|
-
|
Dividend per Share
2 |
0.1700
|
-
|
-
|
0.1900
|
0.1900
|
0.1900
|
0.2000
|
0.2000
|
0.2000
|
0.2000
|
0.2100
|
0.2100
|
0.2100
|
0.2079
|
-
|
Announcement Date
|
10/11/21
|
15/02/22
|
05/05/22
|
04/08/22
|
08/11/22
|
15/02/23
|
09/05/23
|
08/08/23
|
08/11/23
|
15/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
3,755
|
4,973
|
5,381
|
5,658
|
5,746
|
5,939
|
5,735
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.316
x
|
2.558
x
|
2.097
x
|
2.016
x
|
2.313
x
|
2.168
x
|
1.914
x
|
Free Cash Flow
1 |
2,035
|
1,767
|
2,235
|
2,708
|
947
|
1,253
|
1,475
|
ROE (net income / shareholders' equity)
|
18.5%
|
17.5%
|
28.2%
|
43.5%
|
24.7%
|
22.3%
|
21.9%
|
ROA (Net income/ Total Assets)
|
10.4%
|
10.5%
|
13%
|
15.9%
|
10.4%
|
9.57%
|
9.22%
|
Assets
1 |
9,359
|
5,884
|
330.2
|
7,130
|
10,103
|
11,283
|
14,052
|
Book Value Per Share
2 |
16.30
|
16.90
|
15.70
|
16.90
|
22.20
|
24.10
|
26.40
|
Cash Flow per Share
2 |
5.420
|
3.320
|
3.530
|
4.960
|
3.920
|
4.120
|
-
|
Capex
1 |
-
|
2,192
|
1,742
|
2,116
|
1,500
|
1,500
|
1,500
|
Capex / Sales
|
-
|
95.74%
|
77.86%
|
89.85%
|
56.45%
|
51.01%
|
47.24%
|
Announcement Date
|
17/02/21
|
15/02/22
|
15/02/23
|
15/02/24
|
-
|
-
|
-
|
Last Close Price
28.76
USD Average target price
45.88
USD Spread / Average Target +59.51% Consensus |
1st Jan change
|
Capi.
|
---|
| +2.39% | 12.66B | | +29.68% | 699B | | +25.07% | 571B | | -4.35% | 364B | | +17.65% | 326B | | +3.77% | 286B | | +14.68% | 236B | | +4.71% | 198B | | -12.43% | 194B | | -3.79% | 154B |
Other Pharmaceuticals
|